Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor β1, and activin A: Comparison of a cholangiocarcinoma cell line with primary cultures of non- neoplastic biliary epithelial cells

Hepatology

Volumn 32, Issue 1, 2000, Pages 26-35

  Yokomuro, Shigeki ^a   Tsuji, Hirokazu ^a   Lunz III, John G ^a   Sakamoto, Toshiki ^a   Ezure, Tsukasa ^a   Murase, Noriko ^a   Demetris, Anthony J ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; INTERLEUKIN 6; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 0034234736     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.8535     Document Type: Article

References (50)

1. 1. Celli A, Que FG. Dysregulation of apoptosis in the cholangiopathies and cholangiocarcinoma. Semin Liver Dis 1998;18:177-185.
2. 2. Chu KM, Lai EC, Al-Hadeedi S, Arcilla CE, Jr, Lo CM, Liu CL, Fan ST, Wong J. Intrahepatic cholangiocarcinoma. World J Surg 1997;21:301-306.
3. 3. Kornfeld D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand J Gastroenterol 1997;32:1042-1045.
4. 4. Thuluvath PJ, Rai R, Venbrux AC, Yeo CJ. Cholangiocarcinoma: a review. Gastroenterologist 1997;5:306-315.
5. 5. Liu Z, Sakamoto T, Ezure T, Yokomuro S, Murase N, Michalopoulos G, Demetris AJ. Interleukin-6, hepatocyte growth factor, and their receptors in biliary epithelial cells during a type I ductular reaction in mice: interactions between the periductal inflammatory and stromal cells and the biliary epithelium. HEPATOLOGY 1998;28:1260-1268.
6. 6. Oguey D, Marti U, Reichen J. Epidermal growth factor receptor in chronic bile duct obstructed rats: implications for maintenance of hepatocellular mass. Eur J Cell Biol 1992;59:187-195.
7. 7. Aldana PR, Goerke ME, Carr SC, Tracy TF Jr. The expression of regenerative growth factors in chronic liver injury and repair. J Surg Res 1994;57:711-717.
8. 8. Polimeno L, Azzarone A, Zeng QH, Panella C, Subbotin V, Carr B, Bouzahzah B, et al. Cell proliferation and oncogene expression after bile duct ligation in the rat: evidence of a specific growth effect on bile duct cells. HEPATOLOGY 1995;21:1070-1078.
9. 9. Napoli J, Prentice D, Niinami C, Bishop GA, Desmond P, McCaughan GW. Sequential increases in the intrahepatic expression of epidermal growth factor, basic fibroblast growth factor, and transforming growth factor beta in a bile duct ligated rat model of cirrhosis. HEPATOLOGY 1997;26:624-633.
10. 10. Slott PA, Liu MH, Tavoloni N. Origin, pattern, and mechanism of bile duct proliferation following biliary obstruction in the rat. Gastroenterology 1990;99:466-477.
11. 11. Saperstein LA, Jirtle RL, Farouk M, Thompson HJ, Chung KS, Meyers WC. Transforming growth factor-beta 1 and mannose 6-phosphate/ insulin-like growth factor-II receptor expression during intrahepatic bile duct hyperplasia and biliary fibrosis in the rat. HEPATOLOGY 1994;19:412-417.
12. 12. Milani S, Herbst H, Schuppan D, Stein H, Surrenti C. Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am J Pathol 1991;139:1221-1229.
13. 13. Storto PD, Saidman SL, Demetris AJ, Letessier E, Whiteside TL, Gollin SM. Chromosomal breakpoints in cholangiocarcinoma cell lines. Genes Chromosomes Cancer 1990;2:300-310.
14. 14. Matsumoto K, Fujii H, Michalopoulos G, Fung JJ, Demetris AJ. Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. HEPATOLOGY 1994;20:376-382.
15. 15. McCarthy SA, Symonds HS, Van Dyke T. Regulation of apoptosis in transgenic mice by simian virus 40 T antigen-mediated inactivation of p53. Proc Natl Acad Sci USA 1994;91:3979-3983.
16. 16. Joplin R, Hishida T, Tsubouchi H, Daikuhara Y, Ayres R, Neuberger JM, Strain AJ. Human intrahepatic biliary epithelial cells proliferate in vitro in response to human hepatocyte growth factor. J Clin Invest 1992;90: 1284-1289.
17. 17. Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carty SE. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 1998;227:398-404.
18. 18. Yasuda H, Mine T, Shibata H, Eto Y, Hasegawa Y, Takeuchi T, Asano S, Kojima I. Activin A: an autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes. J Clin Invest 1993;92:1491-1496.
19. 19. Yokomuro S, Lunz JG, Sakamoto T, Ezure T, Murase N, Demetris AJ. The effect of interleukin-6 (IL-6) /gp130 signaling on biliary epithelial cell growth, in vitro. Cytokine 2000;12:726-729.
20. 20. Yasoshima M, Kono N, Sugawara H, Katayanagi K, Harada K, Nakanuma Y. Increased expression of interleukin-6 and tumor necrosis factor-alpha in pathologic biliary epithelial cells: in situ and culture study. Lab Invest 1998:78:89-100.
21. 21. Park J, Gores GJ, Patel T. Lipopolysaccharide induces cholangiocyte proliferation via an interleukin-6-mediated activation of p44/p42 mitogen-activated protein kinase. HEPATOLOGY 1999;29:1037-1043.
22. 22. Okada K, Shimizu Y, Nambe S, Kiguchi K, Watanabe A. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 1994;9:462-467.
23. 23. Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. HEPATOLOGY 1999;30:1128-1133.
24. 24. Lai G-H, Radaeva S, Nakamura T, Sirica AE. Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinal-type" biliary cancer chemically-induced in rat liver. HEPATOLOGY 2000;31:(in press).
25. 25. Sugawara H, Yasoshima M, Katayanagi K, Kono N, Watanabe Y, Harada K, Nakanuma Y. Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma. Histopathology 1998;33:145-153.
26. 26. Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol 1998;29:175-180.
27. 27. Liu Z, Yokomuro S, Sakamoto T, Ezure T, Murase N, Contrucci S, Demetris AJ. The acute response to obstructive cholangiopathy in IL-6 deficient mice: compensation by leukemia inhibitory factor (LIF) suggests importance of gp-130 signaling in the ductular reaction. Liver 2000;20:114-124.
28. 28. Imai Y, Oda H, Aral M, Shimizu S, Nakatsuru Y, Inoue T, Ishikawa T. Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hepatocellular-cholangiocellular carcinomas. Jpn J Cancer Res 1996;87:1056-1062.
29. 29. Rizzi PM, Ryder SD, Portmann B, Ramage JK, Naoumov NV, Williams R. p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut 1996;38:265-268.
30. 30. Keller ET, Wanagat J, Ershler WB. Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci 1996;1:d340-d357.
31. 31. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998;16:249-284.
32. 32. Sturm PD, Baas IO, Clement MJ, Nakeeb A, Johan G, Offerhaus A, Hruban RH, et al. Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area. Int J Cancer 1998;78:695-698.
33. 33. Petmitr S, Pinlaor S, Thousungnoen A, Karalak A, Migasena P. K-ras oncogene and p53 gene mutations in cholangiocarcinoma from Thai patients. Southeast Asian J Trop Med Public Health 1998;29:71-75.
34. 34. Kiba T, Tsuda H, Pairojkul C, Inoue S, Sugimura T, Hirohashi S. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Mol Carcinog 1993;8:312-318.
35. 35. He PM, He S, Garner JA, Ryan SJ, Hinton DR. Retinal pigment epithelial cells secrete and respond to hepatocyte growth factor. Biochem Biophys Res Commun 1998;249:253-257.
36. 36. Tuck AB, Park M, Sterns EE, Boag A, Elliott BE. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 1996;148:225-232.
37. 37. Liu Y, Beedle AB, Lin L, Bell AW, Zarnegar R. Identification of a cell-type-specific transcriptional repressor in the promoter region of the mouse hepatocyte growth factor gene. Mol Cell Biol 1994;14:7046-7058.
38. 38. Presnell SC, Hooth MJ, Borchert KM, Coleman WB, Grisham JW, Smith GJ. Establishment of a functional HGF/C-MET autocrine loop in spontaneous transformants of WB-F344 rat liver stem-like cells. HEPATOLOGY 1998;28:1253-1259.
39. 39. Tsang DK, Crowe DL. The mitogen activated protein kinase pathway is required for proliferation but not invasion of human squamous cell carcinoma lines. Int J Oncol 1999;15:519-523.
40. 40. Liang Q, Mohan RR, Chen L, Wilson SE. Signaling by HGF and KGF in corneal epithelial cells: Ras/MAP kinase and Jak-STAT pathways. Invest Ophthalmol Vis Sci 1998;39:1329-1338.
41. 41. Chess PR, Ryan RM, Finkelstein JN. H441 pulmonary epithelial cell mitogenic effects and signaling pathways in response to HGF and TGF-alpha. Exp Lung Res 1998;24:27-39.
42. 42. Talarmin H, Rescan C, Cariou S, Glaise D, Zanninelli G, Bilodeau M, Loyer P, et al. The mitogen-activated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes. Mol Cell Biol 1999;19:6003-6011.
43. 43. Zauberman A, Oren M, Zipori D. Involvement of p21(WAF1/Cip1), CDK4 and Rb in activin A mediated signaling leading to hepatoma cell growth inhibition. Oncogene 1997;15:1705-1711.
44. 44. Shimizu A, Kato M, Nakao A, Imamura T, ten Dijke P, Heldin CH, Kawabata M, et al. Identification of receptors and Smad proteins involved in activin signalling in a human epidermal keratinocyte cell line. Genes Cells 1998;3:125-134.
45. 45. Datto MB, Hu PP Kowalik TF, Yingling J, Wang XF. The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B. Mol Cell Biol 1997;17: 2030-2037.
46. 46. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA, et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 1997;89:1165-1173.
47. 47. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997;389:631-635.
48. 48. Ishisaki A, Yamato K, Nakao A, Nonaka K, Ohguchi M, ten Dijke P, Nishihara T. Smad7 is an activin-inducible inhibitor of activin-induced growth arrest and apoptosis in mouse B cells. J Biol Chem 1998;273: 24293-4296.
49. 49. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999;397:710-713.
50. 50. Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, Bottinger EP. A mechanism of suppression of TGF-beta/ SMAD signaling by NF-kappaB/RelA. Genes Dev 2000;14:187-197.